CA2626567C - Method of preventive on-demand hormonal contraception - Google Patents

Method of preventive on-demand hormonal contraception Download PDF

Info

Publication number
CA2626567C
CA2626567C CA2626567A CA2626567A CA2626567C CA 2626567 C CA2626567 C CA 2626567C CA 2626567 A CA2626567 A CA 2626567A CA 2626567 A CA2626567 A CA 2626567A CA 2626567 C CA2626567 C CA 2626567C
Authority
CA
Canada
Prior art keywords
progestogen
gestodene
patch
administered
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2626567A
Other languages
English (en)
French (fr)
Other versions
CA2626567A1 (en
Inventor
Karin Schmidt-Gollwitzer
Guenter Stock
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2626567A1 publication Critical patent/CA2626567A1/en
Application granted granted Critical
Publication of CA2626567C publication Critical patent/CA2626567C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2626567A 2005-10-19 2006-10-19 Method of preventive on-demand hormonal contraception Expired - Fee Related CA2626567C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005050729.8 2005-10-19
DE102005050729A DE102005050729A1 (de) 2005-10-19 2005-10-19 Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
PCT/EP2006/010273 WO2007045513A1 (de) 2005-10-19 2006-10-19 Verfahren zur präventiven bedarsweisen hormonalen kontrazeption

Publications (2)

Publication Number Publication Date
CA2626567A1 CA2626567A1 (en) 2007-04-26
CA2626567C true CA2626567C (en) 2013-12-03

Family

ID=37762565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2626567A Expired - Fee Related CA2626567C (en) 2005-10-19 2006-10-19 Method of preventive on-demand hormonal contraception

Country Status (13)

Country Link
US (3) US20080311180A1 (enExample)
EP (1) EP1937275A1 (enExample)
JP (2) JP2009512658A (enExample)
KR (1) KR20080056774A (enExample)
CN (1) CN101340915A (enExample)
BR (1) BRPI0617683A2 (enExample)
CA (1) CA2626567C (enExample)
CR (1) CR9908A (enExample)
DE (1) DE102005050729A1 (enExample)
EC (1) ECSP088390A (enExample)
GT (1) GT200800038A (enExample)
HN (1) HN2008000621A (enExample)
WO (1) WO2007045513A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
WO2010119029A1 (en) * 2009-04-14 2010-10-21 Laboratoire Hra-Pharma Method for on-demand contraception
US20120129825A1 (en) * 2009-04-14 2012-05-24 Andre Ulmann Method for on-demand contraception using levonorgestrel or norgestrel
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
SG11201503275RA (en) 2012-11-22 2015-06-29 Bayer Pharma AG Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105451737B (zh) 2013-05-23 2018-04-10 拜耳医药股份有限公司 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
NZ295365A (en) * 1994-10-24 1999-07-29 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
EP1605949A2 (en) * 1999-08-31 2005-12-21 Schering Aktiengesellschaft Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
AU2003245252A1 (en) * 2002-04-30 2003-11-17 Fmc Corporation Carrageenan based antimicrobial compositions
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
CN1913878B (zh) * 2003-12-12 2010-05-26 拜耳先灵医药股份有限公司 无需渗透促进剂的激素透皮传递

Also Published As

Publication number Publication date
CR9908A (es) 2008-05-21
CN101340915A (zh) 2009-01-07
DE102005050729A1 (de) 2007-04-26
WO2007045513A1 (de) 2007-04-26
US20130089574A1 (en) 2013-04-11
JP2014001239A (ja) 2014-01-09
JP2009512658A (ja) 2009-03-26
GT200800038A (es) 2009-04-01
CA2626567A1 (en) 2007-04-26
ECSP088390A (es) 2008-05-30
KR20080056774A (ko) 2008-06-23
BRPI0617683A2 (pt) 2011-08-02
EP1937275A1 (de) 2008-07-02
US20080311180A1 (en) 2008-12-18
US20070111976A1 (en) 2007-05-17
HN2008000621A (es) 2011-07-22

Similar Documents

Publication Publication Date Title
US20130089574A1 (en) Method of preventive on-demand hormonal contraception
Kuhl Pharmacokinetics of oestrogens and progestogens
EP0686037B1 (en) Hormone replacement therapy
US6995149B1 (en) Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
WO1988000469A1 (en) Combination dosage form for pre-menopausal women
JP2009512658A5 (enExample)
EP0600873B1 (en) Therapeutically effective topical application of st1435
Juchem et al. Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor
Christin-Maitre Use of hormone replacement in females with endocrine disorders
US6642219B1 (en) Progestogen-antiprogestogen regimens
JPH09508911A (ja) デソゲストレルを含有する経皮適用剤
SK2982002A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
HK1126413A (en) Method of preventive on-demand hormonal contraception
AU781836B2 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (HRT)
WO1995001161A1 (en) Pack for use in, and method of hormonal replacement therapy
Castracane et al. Changes in oral contraceptive design since the original release. Commentary on The biological history of the Pill by Roy O. Greep
Purdie et al. Short term effects of SHD 386L and levonorgestrel on bone and mineral metabolism in the postmenopause: a double-blind randomised placebo-controlled trial
WO1994014450A1 (en) Transdermal, multiphasic hormone replacement therapy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151019